Literature DB >> 21168237

Factors associated with recurrence in patients with curatively resected stage I-II lung cancer.

Hyeon-Kyoung Koo1, Sang-Man Jin, Chang-Hoon Lee, Hyo-Jeong Lim, Jae-Joon Yim, Young Tae Kim, Seok-Chul Yang, Chul-Gyu Yoo, Sung Koo Han, Joo Hyun Kim, Young-Soo Shim, Young Whan Kim.   

Abstract

BACKGROUND: Patients with stage I-II non-small cell lung cancer (NSCLC) show variability in recurrence after curative resection. Several factors have been proposed as prognostic of recurrence in previous studies. However, because of the heterogeneity of the populations studied, these reports did not yield consistent results. The aim of our study was to identify risk factors for recurrence in patients with curatively resected stage I-II NSCLC.
METHODS: We reviewed the medical records of pathological stage I-II NSCLC patients after curative surgery performed in a tertiary referral center (Seoul National University Hospital) from January 2002 to December 2004. Demographic factors, radiological, histopathological, and laboratory findings, and surgery-related factors were analyzed. Patients with invasive cancer other than lung cancer that was present 5 years prior to surgery were excluded. The Cox proportional hazard regression model was used for multivariate analyses.
RESULTS: Three hundred and ten patients were included. Among them, local recurrence occurred in 27 patients (8.7%), whereas distant recurrence occurred in 79 patients (25.5%). Adenocarcinoma histology (OR, 2.74; 95% CI, 1.14-6.58; P=0.024), carcinoembryonic antigen (CEA) level>2.3 ng/mL (OR, 2.26; 95% CI, 1.02-5.00; P=0.045), and standard uptake values (SUV) of tumor in positron emission tomography (PET)>4.5 (OR, 5.45; 95% CI, 1.82-16.31; P=0.002) were independent predictors of recurrence in addition to TNM stage. We also constructed a recurrence prediction model based on these findings, which yielded better diagnostic performance than the TNM staging system.
CONCLUSION: Adenocarcinoma histology, CEA level, and SUV of PET could be considered as prognostic factors for recurrence in patients with curatively resected stage I-II NSCLC.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21168237     DOI: 10.1016/j.lungcan.2010.11.013

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  15 in total

1.  BRMS1 expression in resected lung adenocarcinoma.

Authors:  Domenico Galetta; Pamela Pizzutilo; Vito Longo
Journal:  Transl Lung Cancer Res       Date:  2018-12

2.  Gene methylation in liquid biopsy and risk of recurrence in lung cancer.

Authors:  Pasqualino de Antonellis; Antonella De Luca; Nicola Normanno
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

3.  Risk factors associated with recurrence of surgically resected node-positive non-small cell lung cancer.

Authors:  Yoichi Ohtaki; Kimihiro Shimizu; Kyoichi Kaira; Toshiteru Nagashima; Kai Obayashi; Seshiru Nakazawa; Seiichi Kakegawa; Hitoshi Igai; Mitsuhiro Kamiyoshihara; Masahiko Nishiyama; Izumi Takeyoshi
Journal:  Surg Today       Date:  2016-01-19       Impact factor: 2.549

4.  BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis.

Authors:  Peter R Bucciarelli; Kay See Tan; Neel P Chudgar; Whitney Brandt; Joseph Montecalvo; Takashi Eguchi; Yuan Liu; Rania Aly; William D Travis; Prasad S Adusumilli; David R Jones
Journal:  J Thorac Oncol       Date:  2017-10-31       Impact factor: 15.609

5.  Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population.

Authors:  Christopher T Erb; Kevin W Su; Pamela R Soulos; Lynn T Tanoue; Cary P Gross
Journal:  Lung Cancer       Date:  2016-07-19       Impact factor: 5.705

6.  CUG-binding protein 1 (CUGBP1) expression and prognosis of non-small cell lung cancer.

Authors:  W Jiao; J Zhao; M Wang; Y Wang; Y Luo; Y Zhao; D Tang; Y Shen
Journal:  Clin Transl Oncol       Date:  2013-01-29       Impact factor: 3.405

7.  Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy.

Authors:  J L Lopez Guerra; D R Gomez; S H Lin; L B Levy; Y Zhuang; R Komaki; J Jaen; A A Vaporciyan; S G Swisher; J D Cox; Z Liao; D C Rice
Journal:  Ann Oncol       Date:  2012-09-20       Impact factor: 32.976

8.  Prognostic factors in curatively resected pathological stage I lung adenocarcinoma.

Authors:  Yikun Yang; Yousheng Mao; Lin Yang; Jie He; Shugeng Gao; Juwei Mu; Qi Xue; Dali Wang; Jun Zhao; Yushun Gao; Zhirong Zhang; Ningning Ding; Ding Yang
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

9.  Risk factors of postoperative recurrences in patients with clinical stage I NSCLC.

Authors:  Ying-Yi Chen; Tsai-Wang Huang; Wen-Chiuan Tsai; Li-Fan Lin; Jian-Bo Cheng; Hung Chang; Shih-Chun Lee
Journal:  World J Surg Oncol       Date:  2014-01-10       Impact factor: 2.754

Review 10.  Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis.

Authors:  Jing Liu; Min Dong; Xiaorong Sun; Wenwu Li; Ligang Xing; Jinming Yu
Journal:  PLoS One       Date:  2016-01-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.